Doctor Xiaoyan Li

Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients with differential duration of treatment: an analysis of the ARISTOPHANES study

Event: ESC CONGRESS 2019

Topic: Oral Anticoagulation

Session: Atrial fibrillation and oral anticoagulation 3

Access

0

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: the dose subgroup analysis of the ARISTOPHANES study

Event: ESC Congress 2018

Topic: Oral Anticoagulation

Session: Atrial fibrillation - Stroke prevention - General

Access

0

Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants and warfarin among non-valvular atrial fibrillation patients: the ARISTOPHANES study

Event: ESC Congress 2018

Topic: Health Economics

Session: Health economics

Access

0

Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants among non-valvular atrial fibrillation patients: the ARISTOPHANES study

Event: ESC Congress 2018

Topic: Health Economics

Session: Health economics

Access

0

Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients: a dose subgroup analysis of the ARISTOPHANES study

Event: ESC Congress 2018

Topic: Oral Anticoagulation

Session: Atrial fibrillation - Stroke prevention

Access

0

Effectiveness and safety of standard and lower dose apixaban compared to warfarin in non-valvular atrial fibrillation patients: a propensity score matched analysis

Event: ESC CONGRESS 2017

Topic: Atrial fibrillation (AF)

Session: Stroke prevention

Access

0

Effectiveness and safety of apixaban versus warfarin among high-risk subgroups of non-valvular atrial fibrillation patients: a propensity score matched analysis

Event: ESC CONGRESS 2017

Topic: Atrial fibrillation (AF)

Session: Stroke prevention

Access

0

Potential impact of apixaban on hospital resource use in patients with venous thromboembolism

Event: ESC CONGRESS 2016

Topic: Thrombosis and coagulation

Session: Antithrombotics in daily clinical practice

Access

0

Demographic and clinical characteristics associated with initiation of individual oral anticoagulants among patients with newly diagnosed venous thromboembolism

Event: ESC CONGRESS 2016

Topic: Thrombosis and coagulation

Session: Thrombosis and coagulation

Access

0

Doctor Xiaoyan Li

Contributor content

Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients with differential duration of treatment: an analysis of the ARISTOPHANES study

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: the dose subgroup analysis of the ARISTOPHANES study

Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants and warfarin among non-valvular atrial fibrillation patients: the ARISTOPHANES study

Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants among non-valvular atrial fibrillation patients: the ARISTOPHANES study

Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients: a dose subgroup analysis of the ARISTOPHANES study

Effectiveness and safety of standard and lower dose apixaban compared to warfarin in non-valvular atrial fibrillation patients: a propensity score matched analysis

Effectiveness and safety of apixaban versus warfarin among high-risk subgroups of non-valvular atrial fibrillation patients: a propensity score matched analysis

Potential impact of apixaban on hospital resource use in patients with venous thromboembolism

Demographic and clinical characteristics associated with initiation of individual oral anticoagulants among patients with newly diagnosed venous thromboembolism

This platform is supported by